Epilepsy is a serious neurological disorder;however,the effectiveness of current medications is often suboptimal.Recently,stem cell technology has demonstrated remarkable therapeutic potential in addressing various ne...Epilepsy is a serious neurological disorder;however,the effectiveness of current medications is often suboptimal.Recently,stem cell technology has demonstrated remarkable therapeutic potential in addressing various neurological diseases,igniting interest in its applicability for epilepsy treatment.This comprehensive review summarizes different therapeutic approaches utilizing various types of stem cells.Preclinical experiments have explored the use and potential therapeutic effects of mesenchymal stem cells,including genetically modified variants.Clinical trials involving patientderived mesenchymal stem cells have shown promising results,with reductions in the frequency of epileptic seizures and improvements in neurological,cognitive,and motor functions reported.Another promising therapeutic strategy involves neural stem cells.These cells can be cultured outside the body and directed to differentiate into specific cell types.The transplant of neural stem cells has the potential to replace lost inhibitory interneurons,providing a novel treatment avenue for epilepsy.Embryonic stem cells are characterized by their significant capacity for self-renewal and their ability to differentiate into any type of somatic cell.In epilepsy treatment,embryonic stem cells can serve three primary functions:neuron regeneration,the maintenance of cellular homeostasis,and restorative activity.One notable strategy involves differentiating embryonic stem cells intoγ-aminobutyric acidergic neurons for transplantation into lesion sites.This approach is currently undergoing clinical trials and could be a breakthrough in the treatment of refractory epilepsy.Induced pluripotent stem cells share the same genetic background as the donor,thereby reducing the risk of immune rejection and addressing ethical concerns.However,research on induced pluripotent stem cell therapy remains in the preclinical stage.Despite the promise of stem cell therapies for epilepsy,several limitations must be addressed.Safety concerns persist,including issues such as tumor formation,and the low survival rate of transplanted cells remains a significant challenge.Additionally,the high cost of these treatments may be prohibitive for some patients.In summary,stem cell therapy shows considerable promise in managing epilepsy,but further research is needed to overcome its existing limitations and enhance its clinical applicability.展开更多
Significant progress has been achieved in the field of organic solar cells(OSCs). Most devices with power conversion efficiencies(PCEs) exceeding 20% rely predominantly on active materials that incorporate D18 or its ...Significant progress has been achieved in the field of organic solar cells(OSCs). Most devices with power conversion efficiencies(PCEs) exceeding 20% rely predominantly on active materials that incorporate D18 or its derivatives as the donor. In contrast, the PCEs over 20% have been realized as well for OSCs with the non-D18-based donor materials by simultaneously optimizing material properties, active layer morphologies and interface engineering, thereby demonstrating the potential to outperform D18 counterparts. Therefore, this review summarizes an overview of recent advancements in OSCs with the PCEs over20% utilizing the non-D18-based donor materials, and highlights three critical aspects including molecular design strategies,the active layer morphologies, and the interface optimization. Their synergistic roles are advantageous in enhancing the exciton dissociation, facilitating the charge transport, and suppressing the recombination losses, accordingly supporting the improved PCEs over 20%. Furthermore, the challenges and valuable insights are discussed, which can lead to improved efficiency, scalable fabrication, and enhanced environmental and thermal stability, potentially accelerating the commercialization of OSCs.展开更多
Conventional ultrasound(US)evaluation of enthesitis in psoriatic arthritis(PsA)is limited by its inability to quantify metabolic alterations such as hypoxia,a key driver of disease activity.We introduce an oxygenation...Conventional ultrasound(US)evaluation of enthesitis in psoriatic arthritis(PsA)is limited by its inability to quantify metabolic alterations such as hypoxia,a key driver of disease activity.We introduce an oxygenation-integrated multimodal photoacoustic/ultrasound(PA/US)imaging framework designed to quantify entheseal oxygen saturation(SO_(2))for assessing entheseal disease activity in PsA.In this cross-sectional study,25 PsA patients underwent bilateral PA/US imaging of 12 entheses,where ultrasound lesions were scored using the Outcome Measures in Rheumatology scoring system,and PA-derived SO_(2) levels,quantified via dual-wavelength PA imaging,were classified into hyperoxia or hypoxia groups using k-means clustering.This approach provides metabolic insights complementary to conventional ultrasonic assessment.A composite score integrating hypoxia with US parameters was validated against clinical disease activity indices(Disease Activity Score 28-C-reactive protein,DAS28-CRP;Disease Activity Index for Psoriatic Arthritis,DAPSA).Among 300 entheses,103(34.3%)exhibited PA positivity,with 40(38.8%)classified as hypoxia.Hypoxia scores independently predicted DAS28-CRP(β=0.618,p=0.001)and DAPSA(β=0.612,p<0:001).The hypoxia-optimized PAUS score demonstrated superior correlation with disease activity indices compared to conventional US(DAS28-CRP:r=0.615,p=0.001 versus r=0.474,p=0.017;DAPSA:r=0.743,p<0:001 versus r=0.567,p=0.003),alongside superior diagnostic accuracy for minimal disease activity(area under the curve,AUC 0.776 versus 0.614,p=0.008)and low disease activity(AUC 0.853 versus 0.772,p=0.009).This multimodal scoring system enhances the stratification of PsA disease activity by providing unique metabolic insights,offering a potential tool for therapeutic monitoring and guiding treat-to-target strategies.展开更多
基金supported by the National Natural Science Foundation of China,Nos.82471471(to WJ),82471485(to FY)Shaanxi Province Special Support Program for Leading Talents in Scientific and Technological Innovation,No.tzjhjw(to WJ)+1 种基金Shaanxi Key Research and Development Plan Project,No.2023-YBSF-353(to XW)the Joint Fund Project of Innovation Research Institute of Xijing Hospital,No.LHJJ24JH13(to ZS)。
文摘Epilepsy is a serious neurological disorder;however,the effectiveness of current medications is often suboptimal.Recently,stem cell technology has demonstrated remarkable therapeutic potential in addressing various neurological diseases,igniting interest in its applicability for epilepsy treatment.This comprehensive review summarizes different therapeutic approaches utilizing various types of stem cells.Preclinical experiments have explored the use and potential therapeutic effects of mesenchymal stem cells,including genetically modified variants.Clinical trials involving patientderived mesenchymal stem cells have shown promising results,with reductions in the frequency of epileptic seizures and improvements in neurological,cognitive,and motor functions reported.Another promising therapeutic strategy involves neural stem cells.These cells can be cultured outside the body and directed to differentiate into specific cell types.The transplant of neural stem cells has the potential to replace lost inhibitory interneurons,providing a novel treatment avenue for epilepsy.Embryonic stem cells are characterized by their significant capacity for self-renewal and their ability to differentiate into any type of somatic cell.In epilepsy treatment,embryonic stem cells can serve three primary functions:neuron regeneration,the maintenance of cellular homeostasis,and restorative activity.One notable strategy involves differentiating embryonic stem cells intoγ-aminobutyric acidergic neurons for transplantation into lesion sites.This approach is currently undergoing clinical trials and could be a breakthrough in the treatment of refractory epilepsy.Induced pluripotent stem cells share the same genetic background as the donor,thereby reducing the risk of immune rejection and addressing ethical concerns.However,research on induced pluripotent stem cell therapy remains in the preclinical stage.Despite the promise of stem cell therapies for epilepsy,several limitations must be addressed.Safety concerns persist,including issues such as tumor formation,and the low survival rate of transplanted cells remains a significant challenge.Additionally,the high cost of these treatments may be prohibitive for some patients.In summary,stem cell therapy shows considerable promise in managing epilepsy,but further research is needed to overcome its existing limitations and enhance its clinical applicability.
基金support from the National Key Research and Development Program of China (2022YFB3803300)the National Natural Science Foundation of China (U23A20138 and 52173192)Hunan Provincial Major Basic Research Project (2025JC0004)。
文摘Significant progress has been achieved in the field of organic solar cells(OSCs). Most devices with power conversion efficiencies(PCEs) exceeding 20% rely predominantly on active materials that incorporate D18 or its derivatives as the donor. In contrast, the PCEs over 20% have been realized as well for OSCs with the non-D18-based donor materials by simultaneously optimizing material properties, active layer morphologies and interface engineering, thereby demonstrating the potential to outperform D18 counterparts. Therefore, this review summarizes an overview of recent advancements in OSCs with the PCEs over20% utilizing the non-D18-based donor materials, and highlights three critical aspects including molecular design strategies,the active layer morphologies, and the interface optimization. Their synergistic roles are advantageous in enhancing the exciton dissociation, facilitating the charge transport, and suppressing the recombination losses, accordingly supporting the improved PCEs over 20%. Furthermore, the challenges and valuable insights are discussed, which can lead to improved efficiency, scalable fabrication, and enhanced environmental and thermal stability, potentially accelerating the commercialization of OSCs.
基金supported by the National Natural Science Foundation of China(62325112)the National Key Research and Development Program of China(2023YFC2411700,2023YFC2411705)+2 种基金the National Natural Science Foundation of China(U22A2023)the National High-Level Hospital Clinical Research Funding(2022-PUMCH-C-009,2022-PUMCH-B-064,2022-PUMCH-D-002)the National Basic Research Program of China(973 Program,2014CB541801).
文摘Conventional ultrasound(US)evaluation of enthesitis in psoriatic arthritis(PsA)is limited by its inability to quantify metabolic alterations such as hypoxia,a key driver of disease activity.We introduce an oxygenation-integrated multimodal photoacoustic/ultrasound(PA/US)imaging framework designed to quantify entheseal oxygen saturation(SO_(2))for assessing entheseal disease activity in PsA.In this cross-sectional study,25 PsA patients underwent bilateral PA/US imaging of 12 entheses,where ultrasound lesions were scored using the Outcome Measures in Rheumatology scoring system,and PA-derived SO_(2) levels,quantified via dual-wavelength PA imaging,were classified into hyperoxia or hypoxia groups using k-means clustering.This approach provides metabolic insights complementary to conventional ultrasonic assessment.A composite score integrating hypoxia with US parameters was validated against clinical disease activity indices(Disease Activity Score 28-C-reactive protein,DAS28-CRP;Disease Activity Index for Psoriatic Arthritis,DAPSA).Among 300 entheses,103(34.3%)exhibited PA positivity,with 40(38.8%)classified as hypoxia.Hypoxia scores independently predicted DAS28-CRP(β=0.618,p=0.001)and DAPSA(β=0.612,p<0:001).The hypoxia-optimized PAUS score demonstrated superior correlation with disease activity indices compared to conventional US(DAS28-CRP:r=0.615,p=0.001 versus r=0.474,p=0.017;DAPSA:r=0.743,p<0:001 versus r=0.567,p=0.003),alongside superior diagnostic accuracy for minimal disease activity(area under the curve,AUC 0.776 versus 0.614,p=0.008)and low disease activity(AUC 0.853 versus 0.772,p=0.009).This multimodal scoring system enhances the stratification of PsA disease activity by providing unique metabolic insights,offering a potential tool for therapeutic monitoring and guiding treat-to-target strategies.
